Biodexa Pharmaceuticals Plc ADR (BDRX)

$1.13 0.00 (N/A)
Market Cap 770,000.00
Revenue (ttm) 0.00
Net Income (ttm) -7.32M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.04
Volume 117,400
Avg Vol 754,294
Day's Range N/A - N/A
Shares Out 682,000.00
Stochastic %K 20%
Beta 1.01
Analysts Strong Buy
Price Target $18.00

Company Profile

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of familial adenomatous polyposis, non-muscle invasive bladder cancer, and Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies...

Industry: Biotechnology
Sector: Healthcare
Phone: 44 29 2048 0180
Address:
1 Caspian Point, Caspian Way, Cardiff, United Kingdom
zzzzzzzzzzzxxx
zzzzzzzzzzzxxx Feb. 27 at 5:26 PM
$HURA this IS a real call. I told you when to buy now like @Love_To_Learn in $PSTV $BDRX years talking shix to his followers fornnothing. 99% money lost. Now he is selling a new level of stupidity. The King of the world sending orders to presidents and he is the new JC. What a clown and distespectful clown he is.
0 · Reply
zzzzzzzzzzzxxx
zzzzzzzzzzzxxx Feb. 27 at 5:08 AM
$BDRX bagggggiiiesss
0 · Reply
jsmith14
jsmith14 Feb. 27 at 12:43 AM
$BDRX this will have its day, until then more red
0 · Reply
Love_To_Learn
Love_To_Learn Feb. 26 at 8:00 PM
$BDRX u r a very bad girl!
1 · Reply
Love_To_Learn
Love_To_Learn Feb. 26 at 7:58 PM
$PSTV $BDRX took some dilution of u using 2 stocks today also aid in panodora spacing from beloved they both dipped heavy*
0 · Reply
Love_To_Learn
Love_To_Learn Feb. 26 at 2:06 PM
$BDRX using some of your movement market wise * sit tight beud
0 · Reply
Love_To_Learn
Love_To_Learn Feb. 25 at 12:34 PM
$BDRX implementing your post rs move to 3pt and crash immediately post rs few rs's ago 4 markets! need this 4 pandora and crypto as she moves across global markets
0 · Reply
thatboytrades
thatboytrades Feb. 24 at 7:27 PM
$BDRX cost free! your 1.30 short entry aint going anywhere kiddoyyyy
0 · Reply
zzzzzzzzzzzxxx
zzzzzzzzzzzxxx Feb. 24 at 6:53 PM
$BDRX baggggyyyyy
0 · Reply
thatboytrades
thatboytrades Feb. 24 at 5:20 PM
$BDRX paying fees to hold your short?
0 · Reply
Latest News on BDRX
Biodexa Licenses Phase 1 Ready Drug Candidate from Otsuka for Rare Stomach Cancer

Feb 19, 2026, 7:30 AM EST - 8 days ago

Biodexa Licenses Phase 1 Ready Drug Candidate from Otsuka for Rare Stomach Cancer

Biodexa Announces Exclusive License of Otsuka's OPB-171775, a potent Phase 1 ready Molecular Glue for GIST

Feb 4, 2026, 8:30 AM EST - 23 days ago

Biodexa Announces Exclusive License of Otsuka's OPB-171775, a potent Phase 1 ready Molecular Glue for GIST

Appointment of Fiona Sharp to the Board as Chief Financial Officer and Company Secretary

Jan 5, 2026, 8:30 AM EST - 7 weeks ago

Appointment of Fiona Sharp to the Board as Chief Financial Officer and Company Secretary

Biodexa Announces Pricing of $10 Million Public Offering

Dec 18, 2025, 8:30 AM EST - 2 months ago

Biodexa Announces Pricing of $10 Million Public Offering

Biodexa Announces Enrolment of First European Patients into Pivotal Phase 3 Serenta Trial in FAP

Dec 1, 2025, 8:30 AM EST - 3 months ago

Biodexa Announces Enrolment of First European Patients into Pivotal Phase 3 Serenta Trial in FAP

Biodexa Activates First European Site for Registrational Phase 3 Serenta Trial in FAP

Nov 24, 2025, 8:30 AM EST - 3 months ago

Biodexa Activates First European Site for Registrational Phase 3 Serenta Trial in FAP

Biodexa Announces Approval of CTA in Europe for Phase 3 Serenta Trial in FAP First European patient expected to be enrolled in 4Q 2025 Addressable US - European Market Put at $7 Billion

Nov 3, 2025, 8:30 AM EST - 4 months ago

Biodexa Announces Approval of CTA in Europe for Phase 3 Serenta Trial in FAP First European patient expected to be enrolled in 4Q 2025 Addressable US - European Market Put at $7 Billion

Biodexa to Host Breakfast Symposium on FAP Mechanisms and Chemoprevention Trial Issues at CGA – IGC Conference on October 11, 2025

Oct 6, 2025, 8:30 AM EDT - 5 months ago

Biodexa to Host Breakfast Symposium on FAP Mechanisms and Chemoprevention Trial Issues at CGA – IGC Conference on October 11, 2025

Interim results for the six months ended June 30, 2025

Sep 12, 2025, 8:30 AM EDT - 6 months ago

Interim results for the six months ended June 30, 2025

Biodexa Moves Into Phase 3 With eRapa For FAP With First Patients Enrolled

Sep 8, 2025, 7:00 AM EDT - 6 months ago

Biodexa Moves Into Phase 3 With eRapa For FAP With First Patients Enrolled

Biodexa Announces Enrolment of First Patients into Pivotal Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP)

Aug 18, 2025, 8:30 AM EDT - 6 months ago

Biodexa Announces Enrolment of First Patients into Pivotal Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP)

ADR Ratio Change Effective

Jul 31, 2025, 9:30 AM EDT - 7 months ago

ADR Ratio Change Effective

How Biodexa Is Racing To Get Its Phase 3 Program in FAP Under Way And Gain First-Mover Advantage in a $7Bn Addressable Market

Jul 28, 2025, 7:00 AM EDT - 7 months ago

How Biodexa Is Racing To Get Its Phase 3 Program in FAP Under Way And Gain First-Mover Advantage in a $7Bn Addressable Market

ADR Ratio Change

Jul 15, 2025, 4:30 PM EDT - 8 months ago

ADR Ratio Change

Biodexa Announces Filing of CTA in Europe for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP)

Jul 14, 2025, 8:30 AM EDT - 8 months ago

Biodexa Announces Filing of CTA in Europe for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP)

Results of Annual General Meeting

Jun 27, 2025, 8:30 AM EDT - 8 months ago

Results of Annual General Meeting

Biodexa Announces Activation of First Clinical Study Site for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP)

Jun 25, 2025, 8:30 AM EDT - 8 months ago

Biodexa Announces Activation of First Clinical Study Site for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP)

Biodexa Unveils "Serenta" as the Name of its Upcoming Phase 3 Study In Familial Adenomatous Polyposis (FAP)

Jun 23, 2025, 8:30 AM EDT - 8 months ago

Biodexa Unveils "Serenta" as the Name of its Upcoming Phase 3 Study In Familial Adenomatous Polyposis (FAP)

Biodexa Hits Key Milestone For Its Type 1 Diabetes Candidate Tolimidone, Enrolls First Patient In Phase 2a Study

Jun 18, 2025, 7:00 AM EDT - 9 months ago

Biodexa Hits Key Milestone For Its Type 1 Diabetes Candidate Tolimidone, Enrolls First Patient In Phase 2a Study

Result of General Meeting

Jun 11, 2025, 4:30 PM EDT - 9 months ago

Result of General Meeting

Biodexa Announces Recruitment of First Patient in Phase 2 Study of Tolimidone in Type 1 Diabetes

Jun 4, 2025, 8:30 AM EDT - 9 months ago

Biodexa Announces Recruitment of First Patient in Phase 2 Study of Tolimidone in Type 1 Diabetes

Shareholder Update

May 30, 2025, 8:30 AM EDT - 9 months ago

Shareholder Update

Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Notice of General Meeting

May 22, 2025, 4:30 PM EDT - 10 months ago

Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Notice of General Meeting

Biodexa Announces Award of Additional $3.0M Grant from CPRIT to Support Registrational eRapa Phase 3 Program in FAP Brings Total CPRIT Grant Funding for eRapa Phase 3 Program to $20.0M

May 22, 2025, 8:30 AM EDT - 10 months ago

Biodexa Announces Award of Additional $3.0M Grant from CPRIT to Support Registrational eRapa Phase 3 Program in FAP Brings Total CPRIT Grant Funding for eRapa Phase 3 Program to $20.0M

Biodexa Receives Orphan Drug Designation in Europe for eRapa in FAP

May 12, 2025, 8:30 AM EDT - 10 months ago

Biodexa Receives Orphan Drug Designation in Europe for eRapa in FAP

Notice of General Meeting

Apr 17, 2025, 8:30 AM EDT - 11 months ago

Notice of General Meeting

Preliminary Results for the Year Ended 31 December 2024

Apr 11, 2025, 8:30 AM EDT - 11 months ago

Preliminary Results for the Year Ended 31 December 2024

With Fast Track Designation in Hand, a Successful Protocol Discussion with FDA, and CROs in Place, Biodexa is on Track to Initiate its Funded Phase 3 Trial in FAP Next Quarter

Mar 19, 2025, 7:00 AM EDT - 1 year ago

With Fast Track Designation in Hand, a Successful Protocol Discussion with FDA, and CROs in Place, Biodexa is on Track to Initiate its Funded Phase 3 Trial in FAP Next Quarter

Biodexa Announces Successful Outcome of a Type C Meeting with FDA Regarding the Phase 3 Program for eRapa in FAP

Mar 10, 2025, 8:30 AM EDT - 1 year ago

Biodexa Announces Successful Outcome of a Type C Meeting with FDA Regarding the Phase 3 Program for eRapa in FAP

Biodexa Announces Appointment of Precision for Medicine LLC as CRO for European Component of Phase 3 Study of eRapa in FAP

Mar 6, 2025, 8:30 AM EST - 1 year ago

Biodexa Announces Appointment of Precision for Medicine LLC as CRO for European Component of Phase 3 Study of eRapa in FAP

Biodexa Announces Allowance of U.S. Patent Covering Oral Rapamycin Nanoparticle Preparations (“eRapa”) and Use

Feb 24, 2025, 8:30 AM EST - 1 year ago

Biodexa Announces Allowance of U.S. Patent Covering Oral Rapamycin Nanoparticle Preparations (“eRapa”) and Use

Biodexa Pharmaceuticals PLC to Present at the Emerging Growth Conference on February 19, 2025

Feb 13, 2025, 8:30 AM EST - 1 year ago

Biodexa Pharmaceuticals PLC to Present at the Emerging Growth Conference on February 19, 2025

Following Positive Phase 2 Results and Orphan Drug Designation, Biodexa's FAP Drug Receives FDA Fast Track Status

Feb 12, 2025, 7:30 AM EST - 1 year ago

Following Positive Phase 2 Results and Orphan Drug Designation, Biodexa's FAP Drug Receives FDA Fast Track Status

Biodexa Receives US FDA Fast Track Designation for eRapa in Familial Adenomatous Polyposis

Feb 10, 2025, 8:30 AM EST - 1 year ago

Biodexa Receives US FDA Fast Track Designation for eRapa in Familial Adenomatous Polyposis

Biodexa Strengthens Management Team - Appointment of Dr Gary A. Shangold as Chief Medical Officer

Jan 22, 2025, 8:30 AM EST - 1 year ago

Biodexa Strengthens Management Team - Appointment of Dr Gary A. Shangold as Chief Medical Officer

Gaining Momentum, Biodexa is Advancing Two Recent Acquisitions Through the Clinic

Nov 21, 2024, 7:35 AM EST - 1 year ago

Gaining Momentum, Biodexa is Advancing Two Recent Acquisitions Through the Clinic

Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Regains Compliance For Continued Listing on Nasdaq

Nov 12, 2024, 8:48 AM EST - 1 year ago

Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Regains Compliance For Continued Listing on Nasdaq

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Biodexa Pharmaceuticals Plc (BDRX) And Encourages Shareholders to Reach Out

Oct 31, 2024, 10:00 AM EDT - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Biodexa Pharmaceuticals Plc (BDRX) And Encourages Shareholders to Reach Out

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Biodexa Pharmaceuticals Plc (BDRX) and Encourages Investors to Learn More About the Investigation

Oct 30, 2024, 10:00 AM EDT - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Biodexa Pharmaceuticals Plc (BDRX) and Encourages Investors to Learn More About the Investigation

Biodexa Pharmaceuticals Plc (BDRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Oct 29, 2024, 10:00 AM EDT - 1 year ago

Biodexa Pharmaceuticals Plc (BDRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Biodexa Pharmaceuticals Plc (BDRX) And Encourages Stockholders to Reach Out

Oct 28, 2024, 10:00 AM EDT - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Biodexa Pharmaceuticals Plc (BDRX) And Encourages Stockholders to Reach Out

Bronstein, Gewirtz & Grossman, LLC Is Investigating Biodexa Pharmaceuticals Plc (BDRX) And Encourages Stockholders to Connect

Oct 27, 2024, 10:00 AM EDT - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Biodexa Pharmaceuticals Plc (BDRX) And Encourages Stockholders to Connect

zzzzzzzzzzzxxx
zzzzzzzzzzzxxx Feb. 27 at 5:26 PM
$HURA this IS a real call. I told you when to buy now like @Love_To_Learn in $PSTV $BDRX years talking shix to his followers fornnothing. 99% money lost. Now he is selling a new level of stupidity. The King of the world sending orders to presidents and he is the new JC. What a clown and distespectful clown he is.
0 · Reply
zzzzzzzzzzzxxx
zzzzzzzzzzzxxx Feb. 27 at 5:08 AM
$BDRX bagggggiiiesss
0 · Reply
jsmith14
jsmith14 Feb. 27 at 12:43 AM
$BDRX this will have its day, until then more red
0 · Reply
Love_To_Learn
Love_To_Learn Feb. 26 at 8:00 PM
$BDRX u r a very bad girl!
1 · Reply
Love_To_Learn
Love_To_Learn Feb. 26 at 7:58 PM
$PSTV $BDRX took some dilution of u using 2 stocks today also aid in panodora spacing from beloved they both dipped heavy*
0 · Reply
Love_To_Learn
Love_To_Learn Feb. 26 at 2:06 PM
$BDRX using some of your movement market wise * sit tight beud
0 · Reply
Love_To_Learn
Love_To_Learn Feb. 25 at 12:34 PM
$BDRX implementing your post rs move to 3pt and crash immediately post rs few rs's ago 4 markets! need this 4 pandora and crypto as she moves across global markets
0 · Reply
thatboytrades
thatboytrades Feb. 24 at 7:27 PM
$BDRX cost free! your 1.30 short entry aint going anywhere kiddoyyyy
0 · Reply
zzzzzzzzzzzxxx
zzzzzzzzzzzxxx Feb. 24 at 6:53 PM
$BDRX baggggyyyyy
0 · Reply
thatboytrades
thatboytrades Feb. 24 at 5:20 PM
$BDRX paying fees to hold your short?
0 · Reply
zzzzzzzzzzzxxx
zzzzzzzzzzzxxx Feb. 24 at 3:10 PM
$BDRX below UNO sooooon
0 · Reply
Love_To_Learn
Love_To_Learn Feb. 24 at 12:08 PM
$BDRX been keeping u on a leash as ive lowered u changed future due to few things 1 being the sls and also timing everything from months back *
1 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 23 at 1:20 PM
$BDRX RSI: 25.20, MACD: -0.3883 Vol: 0.39, MA20: 1.53, MA50: 2.56 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
zzzzzzzzzzzxxx
zzzzzzzzzzzxxx Feb. 21 at 2:22 AM
$BDRX lmao beaud @Love_To_Learn one of the most impressive scam of hungryearner.only compares with $PSTV nuwe ghsi akba envb taop Happy jagx avgr lmaooo
0 · Reply
thatboytrades
thatboytrades Feb. 20 at 9:57 PM
$BDRX i am also Mo’ mashallah
1 · Reply
zzzzzzzzzzzxxx
zzzzzzzzzzzxxx Feb. 20 at 5:59 PM
$BDRX deadmeat
0 · Reply
thatboytrades
thatboytrades Feb. 20 at 3:46 PM
$BDRX alhamdulilah
0 · Reply
zzzzzzzzzzzxxx
zzzzzzzzzzzxxx Feb. 20 at 3:23 PM
$BDRX scam of the year but no problem @Love_To_Learn Will protect you
0 · Reply
zzzzzzzzzzzxxx
zzzzzzzzzzzxxx Feb. 20 at 2:59 PM
$BDRX lmao
0 · Reply
TONYVANNA7677
TONYVANNA7677 Feb. 20 at 12:43 PM
$BDRX start party 💥
0 · Reply
zzzzzzzzzzzxxx
zzzzzzzzzzzxxx Feb. 20 at 3:37 AM
$BDRX below 1 soooon
0 · Reply
zzzzzzzzzzzxxx
zzzzzzzzzzzxxx Feb. 20 at 3:35 AM
$BDRX dilution
0 · Reply